Login to Your Account

Achillion sets stage for future Sovaldi battle with proxy study

By Michael Fitzhugh
Staff Writer

Friday, August 15, 2014

Interim phase II data showing that an eight-week course of Achillion Pharmaceuticals Inc.'s NS5A inhibitor, ACH-3102, and Sovaldi (sofosbuvir, Gilead Sciences Inc.) in 12 hepatitis C virus (HCV) genotype 1 patients resulted in a complete sustained virologic response rate four weeks after treatment (SVR4) pushed company shares (Nasdaq:ACHN) up 9.6 percent to close at $9.25 Friday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription